{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:24:34Z","timestamp":1791336274969,"version":"4.3.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":1535,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jchf.2013.07.007","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T16:16:16Z","timestamp":1389197776000},"page":"1-14","source":"Crossref","is-referenced-by-count":55,"title":["Antiplatelet and Anticoagulant Agents in Heart Failure"],"prefix":"10.1016","volume":"2","author":[{"given":"Paul A.","family":"Gurbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2013.07.007_bib1","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib2","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ijcard.2012.12.018","article-title":"Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges","volume":"167","author":"Zannad","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cardfail.2007.01.009","article-title":"The incidence of ischemic stroke in chronic heart failure: a meta-analysis","volume":"13","author":"Witt","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.54.2.288","article-title":"Stroke in patients with heart failure and reduced left ventricular ejection fraction","volume":"54","author":"Pullicino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jchf.2013.07.007_bib5","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2013.07.007_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14779072.2.4.535","article-title":"Platelet activation in myocardial ischemic syndromes","volume":"2","author":"Gurbel","year":"2004","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jchf.2013.07.007_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/CIRCULATIONAHA.110.952648","article-title":"Thrombin generation in hemorrhage control and vascular occlusion","volume":"124","author":"Mann","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9149(99)00098-3","article-title":"Usefulness of soluble and surface bound P-selectin in detecting heightened platelet activity in patients with chronic heart failure","volume":"83","author":"O'Connor","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1388-9842(02)00026-0","article-title":"Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial)","volume":"4","author":"Serebruany","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003495-200363060-00004","article-title":"Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention","volume":"63","author":"De Lorenzo","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jchf.2013.07.007_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9149(99)00098-3","article-title":"Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure","volume":"83","author":"O'Connor","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1388-9842(03)00110-7","article-title":"Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure","volume":"5","author":"Stumpf","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1160\/TH04-05-0278","article-title":"Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure","volume":"92","author":"Alehagen","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jchf.2013.07.007_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1160\/TH08-05-0330","article-title":"Increased plasma von Willebrand factor antigen\u00a0levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia","volume":"101","author":"Molvarec","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jchf.2013.07.007_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1084\/jem.163.3.740","article-title":"Modulation of endothelial cell hemostatic properties by tumor necrosis factor","volume":"163","author":"Nawroth","year":"1986","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib17","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000083845","article-title":"Virchow's triad revisited: abnormal flow","volume":"33","author":"Lowe","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jchf.2013.07.007_bib19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00109-006-0101-1","article-title":"The impact of blood rheology on the molecular and cellular events underlying arterial thrombosis","volume":"84","author":"Nesbitt","year":"2006","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation-2004.1.439","article-title":"Deep venous thrombosis","author":"Lopez","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jchf.2013.07.007_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000068427","article-title":"Principle mechanisms underlying venous thromboembolism; epidemiology, risk factors, pathophysiology and pathogenesis","volume":"70","author":"Kroegel","year":"2003","journal-title":"Respiration"},{"key":"10.1016\/j.jchf.2013.07.007_bib22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jacc.2004.12.075","article-title":"Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism","volume":"45","author":"Chirinos","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib23","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2013.07.007_bib24","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.cardfail.2004.06.133","article-title":"Endothelial, platelet and leukocyte activation in patients with congestive heart failure","volume":"10","author":"Carpio","year":"2004","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib25","doi-asserted-by":"crossref","first-page":"14A","DOI":"10.1016\/0735-1097(93)90456-B","article-title":"Natural history and patterns of current practice in heart failure","volume":"22","author":"Bourassa","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2013.07.007_bib28","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1161\/CIRCULATIONAHA.106.661397","article-title":"SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)","volume":"115","author":"Freudenberger","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurjhf\/hfr172","article-title":"Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study","volume":"14","author":"Vemmos","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1052-3057(10)80166-1","article-title":"Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study","volume":"5","year":"1995","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jchf.2013.07.007_bib31","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1586\/erc.12.148","article-title":"New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation","volume":"10","author":"Ahmad","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jchf.2013.07.007_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/01.CIR.60.3.497","article-title":"Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside","volume":"60","author":"Mehta","year":"1979","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jchf.2013.07.007_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000975","article-title":"Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study","volume":"2","author":"Lip","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jchf.2013.07.007_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10654-010-9520-y","article-title":"Heart failure and the risk of stroke: the Rotterdam Study","volume":"25","author":"Alberts","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM199701233360403","article-title":"Ventricular dysfunction and the risk of stroke after myocardial infarction","volume":"336","author":"Loh","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjmed.2010.10.014","article-title":"Venous thromboembolism in heart failure: preventable deaths during and after hospitalization","volume":"124","author":"Piazza","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH11-03-0168","article-title":"Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in\u00a0Europe show underutilisation of preventive therapies","volume":"106","author":"Khoury","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jchf.2013.07.007_bib38","article-title":"Incidence of thromboembolic events in congestive heart failure","volume":"87","author":"Dunkman","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib39","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","article-title":"Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents","volume":"125","author":"Gurbel","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib40","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2013.07.007_bib43","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2013.07.007_bib44","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib45","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2013.07.007_bib46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib47","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2013.07.007_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/pgs.11.184","article-title":"Prediction of warfarin dose: why, when and how?","volume":"13","author":"Eriksson","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jchf.2013.07.007_bib49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2004.11.025","article-title":"Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal","volume":"117","author":"Oden","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.jchf.2013.07.007_bib51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib52","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0049-3848(10)70147-X","article-title":"Factor Xa and thrombin as targets for new oral anticoagulants","volume":"127","author":"Weitz","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jchf.2013.07.007_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurjhf\/hfs073","article-title":"Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis","volume":"14","author":"Lip","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM194811042391902","article-title":"Dicumarol therapy in congestive heart failure","volume":"239","author":"Wishart","year":"1948","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1056\/NEJM195002092420603","article-title":"Dicumarol prophylaxis of thromboembolic disease in congestive heart failure","volume":"242","author":"Harvey","year":"1950","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib56","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-37-5-867","article-title":"A\u00a0study of the beneficial effects of anticoagulant therapy in congestive heart failure","volume":"37","author":"Griffith","year":"1952","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0735-1097(98)00006-0","article-title":"Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib58","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0735-1097(99)00129-1","article-title":"Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease","volume":"33","author":"Leor","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9149(96)00696-0","article-title":"Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"79","author":"Nguyen","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib60","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2013.07.007_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic therapies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2013.07.007_bib62","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib63","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2013.07.007_bib64","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib65","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1056\/NEJMe1202504","article-title":"Warfarin in heart failure","volume":"366","author":"Eikelboom","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib66","doi-asserted-by":"crossref","unstructured":"Homma S. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF) trial. Paper presented at: Heart Failure Society of\u00a0America\u00a02012 Scientific Meeting; September 10, 2012; Seattle, WA.","DOI":"10.1016\/j.cardfail.2012.10.002"},{"key":"10.1016\/j.jchf.2013.07.007_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/eurjhf\/hfs171","article-title":"Updated meta-analysis on anti-thrombotic therapy in patients with heart failure and sinus rhythm","volume":"15","author":"Hopper","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib68","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.09.015","article-title":"Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials","volume":"22","author":"Kumar","year":"2013","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jchf.2013.07.007_bib69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.recesp.2011.11.012","article-title":"Anticoagulation therapy in patients with heart failure due to systolic dysfunction and sinus rhythm: analysis of REDINSCOR registry","volume":"65","author":"Avellana","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2013.07.007_bib71","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"Suppl","key":"10.1016\/j.jchf.2013.07.007_bib72","first-page":"232","article-title":"Impact of bivalirudin therapy on mortality in patients with high risk features undergoing PCI: a patient-level pooled analysis from the REPLACE-2, ACUITY, and HORIZONS-AMI trials (abstr)","volume":"32","author":"Dangas","year":"2011","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.jchf.2013.07.007_bib73","first-page":"393","article-title":"Reduction in mortality from thrombin inhibition in CHF patients: results from the premier hospital database (abstr.)","volume":"33","author":"Kohli","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2013.07.007_bib74","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib77","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2013.07.007_bib79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure","volume":"30","author":"Gheorghiade","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2013.07.007_bib80","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib81","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure Practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2013.07.007_bib82","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177913004101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177913004101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:47:53Z","timestamp":1565052473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177913004101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S2213177913004101"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2013.07.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}